Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
This is a somewhat nostalgic retro blog. I was leafing through a book by Vince Andriole called ‘The Quinolones’.[1] First released in 1988, its third edition is from 2000. It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety. It was a great review of the large and Continue reading ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW
Police profiling based on race, sex or gender is a highly controversial practice. FDA doing the same, not so much. Profiling based on similarities to other drugs in the same category is nothing new. Class labeling can be expected for the next new B-lactam or quinolone regardless of whether during Continue reading Profiling Solithromycin: FDA AMDAC on Solithera
Fluoroquinolones (FQ) of the ofloxacin/ciprofloxacin generation were mainly active against Gram-negative bacteria, distinguishing themselves as cidal IV/PO drugs with high potency against most lactose- and non-lactose fermenters. They were excellent against problem pathogens like P. aeruginosa, had excellent efficacy against Salmonellae, the Gonococcus and other Neisseriae, and you could count on them for Continue reading MRSA Fluoroquinolones – An Interesting Bunch Playing a High-Stakes Game